Moradi A, Sepah YJ, Sadiq MA, et al.. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema

World journal of diabetes 12/2013; 4(6):303-309. DOI: 10.4239/wjd.v4.i6.303
Source: PubMed

ABSTRACT Diabetic retinopathy (DR) is the most common cause of visual loss among working age individuals. Diabetic macular edema (DME) is an important complication of DR that affects around one third of the patients with DR. Several treatments have been approved for DME ranging from blood pressure and glycemic control to photocoagulation and more recently the use of vascular endothelial growth factor (VEGF) antagonists. The index review discusses aflibercept (EYLEA(®)-Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) in the context of other VEGF antagonists currently available for the treatment of DME. A systematic search of literature was conducted on PubMed, Scopus, and Google Scholar with no limitation on language or year of publication. Pre-clinical studies of aflibercept have shown a higher affinity of this molecule for vascular endothelial growth factor A (VEGF-A) along with a longer duration of action as compared to other VEGF antagonists. Recent clinical trials have shown visual outcome results for aflibercept to be similarly favorable as compared to other available agents with the added benefit of fewer required injections and less frequent monitoring. Aflibercept presents a potential exciting new addition to the armamentarium of current VEGF antagonists available for the treatment of DME and other retinal vascular diseases. However, further studies are indicated to confirm the role, safety, and efficacy of aflibercept for DME.

Download full-text


Available from: Ahmadreza Moradi, Jan 05, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Currently several anti-angiogenic agents are being widely and successfully used for the treatment of eye diseases like neovascular macular degeneration, retinal vein occlusion and diabetic macular edema. Taking into consideration that these patients may present with a different spectrum of underlying diseases and potentially higher risk profiles, systemic safety data across multiple anti-angiogenic agents should be analyzed critically. Methods: A comprehensive literature search was conducted on Medline, PubMed, and Google Scholar databases in June 2014. Search temporal limits included articles published from 2005 to 2014 with the purpose of providing the most recent evidence. Studies were queried using the following keywords in various combinations: anti-angiogenics in eye diseases, intravitreal pharmacotherapy by anti-VEGF, adverse effects, potential systemic hazards, bevacizumab, pegaptanib sodium, ranibizumab, aflibercept. The articles of high or medium clinical relevance were selected for review. Results: Almost uniformly all trial evaluating systemic safety of anti-angiogenic agents reveal the serious side effects including cardiovascular events, despite the fact that the incidence is low. Systemic safety concern in intraocular pharmacotherapy by anti-angiogenic agents has a strong body of clinical evidence, resulting in plenty of peer reviewed clinical articles. Conclusion Currently available findings obviate the need to raise awareness about cardiovascular risk profile in patients with eye diseases treated by anti-VEGF. Early detection is crucial so that intraocular injections can be stopped before severe accident occurs.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic retinopathy (DR) is the leading cause of vision loss of working-age adults, and diabetic macular edema (DME) is the most frequent cause of vision loss related to diabetes. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found the 14-year incidence of DME in type 1 diabetics to be 26%. Similarly the Diabetes Control and Complications Trial reported that 27% of type 1 diabetic patients develop DME within 9 years of onset. The most common type of diabetes, type 2, is strongly associated with obesity and a sedentary lifestyle. An even higher incidence of macular edema has been reported in older patients with type 2 diabetes. Within the last 5 years, the use of intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor (VEGF) agents have come into clinical practice for the management of DME and several recent randomized clinical trials have shown improved effectiveness of ranibizumab compared to focal/grid laser. In this theme issue, we discuss the classification of DR and the treatment options currently available for the treatment of DME including corticosteroids, anti-VEGF agents, combined therapy, enzymatic vitrectomy (vitreolysis), and new therapies.
    12/2013; 4(6):231-3. DOI:10.4239/wjd.v4.i6.231
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic Retinopathy (DR) is a consequence of diabetes mellitus at the ocular level, leading to vision loss, and contributing to the decrease of patient's life quality. The biochemical and anatomic abnormalities that occurs in DR are discussed in this review to better understand and manage the development of new therapeutic strategies. The use of new drug delivery systems based on nanoparticles (e.g. liposomes, dendrimers, cationic nanoemulsions, lipid and polymeric nanoparticles) is discussed along with the current traditional treatments, pointing out the advantages of the proposed nanomedicines to target this ocular disease. Despite the multifactorial nature of DR, which is not entirely understood, some strategies based on nanoparticles are being exploited for a more efficient drug delivery to the posterior segment of the eye. On the other hand, the use of some nanoparticles also seems to contribute to the development of DR symptoms (e.g. retinal neovascularization), which are also discussed in the light of an efficient management of this ocular chronic disease. Copyright © 2014. Published by Elsevier B.V.
    European Journal of Pharmaceutics and Biopharmaceutics 12/2014; DOI:10.1016/j.ejpb.2014.12.023 · 4.25 Impact Factor
Show more